Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSN16R for Spasticity in Multiple Sclerosis
NCT02542787Phase 2Completed
- Sponsor
- Canbex Therapeutics Ltd
- Start
- Aug 2015
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VSN16R in spasticity (2 arms), sponsored by Canbex Therapeutics Ltd. Primary endpoint: Numerical Rating Scale at 26 days. Started Aug 2015; status: completed.
02
Drugs
VSN16R
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT02542787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02542787.